Oxford BioMedica PLC (OXBDF) reports an 18% revenue increase and significant progress in strategic initiatives for the first ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report). The ...

Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure ...

Oxford Biomedica, which recently rebranded to OXB, told investors that it expected continued growth in the second half of the ...

Discover how Oxford BioMedica's new patent enhances viral vector production efficiency with a novel nucleic acid sequence that regulates therapeutic protein translation.

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic ...

To address the unmet need for a cure for RTT, the therapeutic potential of adult Neural Precursor Cells (NPCs) was ...

A new bioprocessing technique developed by a team of researchers could improve a range of therapies based on CAR-T cells.

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK - 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene the ...